Browsing Tag
FDA fast-track
1 post
Can Amplia’s 31% response rate help narmafotinib break into FDA fast-track territory?
Can Amplia's narmafotinib gain FDA fast-track after 31% pancreatic cancer response rate? Explore its trial results, U.S. plans, and Project Optimus path.